Innate Pharma
FREURInnate Pharma (LSE:0EVI) — Biotechnology: Biological Products (No Diagnostic Substances). Börside arv, kus ettevõtte aktsiatega kaubeldakse: 3. Sellel lehel — hind ja graafik, dividendid, suurimad aktsionärid ja aktsiate arvu ajalugu.
Ettevõtte Kohta
- Veebileht
- innate-pharma.com
- Sektor
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Peakontor
- MARSEILLE, France
- Tegevjuht
- Jonathan E. Dickinson
- Töötajad
- 120
- Asutatud
- 1999
- Ringluses Olevad Aktsiad
- 111.7 mln
- Vabalt Kaubeldavad Aktsiad
- 70.45 mln
- Turukapitalisatsioon
- 146.33 mln EUR
- Siseringi Isikud
- 17.46%
- Institutsionaalsed Investorid
- 10.86%
- Tegevusala (SIC)
- Biological Products, (No Diagnostic Substances)
- Õiguslik Vorm
- K65D
- ISIN
- FR0010331421
- LEI
- 9695002Y8420ZB8HJE29
- P/E
- kahjum
- FCF
- −52.9 mln EUR
- Võlg
- ?
- Kasum ja FCF — 12 kuu jooksul kuni 31.12.2025 (ettevõtte viimane raport).
Kirjeldus
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.
Suurimad Omanikud
| Omanik | Osalus | Aktsiad | Aruande Kuupäev |
|---|---|---|---|
| ETF Series Solutions-Ran… | 0.08% | 72 695 | 2025-02-28 |
| Lion Point Capital, LP | 0.07% | 81 151 | 2026-06-30 |
| Morgan Stanley | 0.04% | 43 524 | 2026-06-30 |
| Smartharvest Portfolios,… | 0.02% | 23 750 | 2026-06-30 |
| Dimensional ETF Trust-Di… | 0.02% | 23 277 | 2026-01-31 |
| Xtx Topco Ltd | 0.01% | 15 130 | 2026-06-30 |
| Citadel Advisors Llc | 0.01% | 12 441 | 2026-06-30 |
| Jane Street Group, LLC | 0.01% | 10 310 | 2026-06-30 |
| Rhumbline Advisers | 0% | 4 719 | 2026-06-30 |
| UBS Group AG | 0% | 1 363 | 2026-06-30 |
| Farther Finance Advisors… | 0% | 21 | 2026-06-30 |
| Gamma Investing LLC | 0% | 9 | 2026-06-30 |
Logi Sisse Google